WASHINGTON — The Personal Care Products Council and the Safe Cosmetics Alliance has announced support for legislation to strengthen and modernize regulatory oversight of the industry and to create a greater role for the Food and Drug Administration in assessing the safety of personal care products.
Introduced by Rep. Leonard Lance, R-N.J., the "Cosmetic Safety Amendments Act of 2012" (H.R. 4395), will modernize federal oversight of cosmetics and personal care products, currently one of the safest product categories regulated by the FDA, and H.R. 4395 builds on that strong record, the council stated.
The proposal has the full support of the council and the Safe Cosmetics Alliance, which have consistently advocated for an updated, enhanced and transparent regulatory framework for FDA.
"FDA regulation of cosmetics has protected the public for decades, and this landmark legislation will enhance protections for millions of American consumers," said Lezlee Westine, PCPC's president and CEO. "Cosmetics companies recognize the need for a modern regulatory process that keeps pace with product innovation, as well as the demand for transparency. The Council applauds Congressman Lance for introducing this bill and will work to help gain bipartisan support for its passage."
The cosmetic and personal care industry employs 8.2 million people, directly or indirectly, in the United States. The industry has an estimated $60 billion in annual American retail sales and is a net exporter. Small businesses with 50 or fewer employees make up 92% of the industry and women represent 66% of its workforce.
H.R. 4395 calls for increased reporting and transparency by the industry and enhanced regulatory oversight without further straining taxpayer resources and damaging small and medium-sized businesses' ability to compete globally and create new manufacturing jobs in the United States.
The legislation aims to create formal processes for the FDA to review ingredients for safety, set safety levels for trace impurities, create national uniformity for cosmetics regulations, review all safety determinations made by the Cosmetic Ingredient Review Expert Panel and establish industry-wide "Good Manufacturing Practices." CIR is an independent panel of scientific and medical experts that assesses the safety of cosmetic ingredients used in the United States. In addition, under the new legislation, the voluntary registration programs for facilities and products would become mandatory, as would the reporting of any serious and unexpected adverse events.
H.R. 4395 builds upon portions of legislation originally introduced by Rep. John Dingell, D-Mich., known as "The FDA Globalization Act of 2008." Rep. Frank Pallone, D-N.J., along with Dingell, recently introduced legislation that has similar provisions to H.R. 4395.
"We look forward to working with Congressman Lance on this legislation," said Westine. "We also look forward to working on a bipartisan basis with Congressmen Pallone and Dingell on legislation that updates FDA regulation of cosmetics and enhances consumer protections."
The new legislation introduced by Congressman Lance makes several enhancements to current law including:
(1) Enhanced FDA Registration. It requires that personal care products manufacturers who market their products in the United States comply with the following:
Register all facilities where those products are manufactured.
File product ingredient reports disclosing ingredients used, consistent with current guidelines.
Report any serious unexpected adverse event with a product experienced by a consumer.
(2) New Process to Set Safety Levels for Trace Constituents. When requested or on its own initiative, FDA would be required to establish safe levels for trace constituents in cosmetic ingredients and products.
(3) New FDA Ingredient Review Process. Once a request has been made, or FDA determines review is warranted, the agency would be required to make a determination about the safety of any ingredient intended for use in a personal care product and set safe use levels for such ingredient on a specified timetable.
(4) New FDA Oversight of CIR Findings. FDA would be required to review current and future findings on the safety of cosmetic ingredients by CIR Expert Panel and determine if these findings are correct. If there are instances in which it determines a CIR finding is unsupported, FDA would determine by guidance or regulations if, or under what conditions, the ingredient can be used safely in cosmetic products.
(5) FDA-Issued Good Manufacturing Practices. FDA would establish industry-wide "Good Manufacturing Practices" requirements.
(6) National Uniformity. FDA's new regulatory authority would preempt similar state legislation for cosmetics and personal care products.